

Soo-Mee Bang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2844304/publications.pdf>

Version: 2024-02-01

168
papers

2,003
citations

279798

23
h-index

330143

37
g-index

172
all docs

172
docs citations

172
times ranked

3543
citing authors

#	ARTICLE	IF	CITATIONS
1	Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2995-3005.	2.5	5
2	JAK2 V617F-Positive Acute Myeloid Leukemia: Clinicopathological Features of Two Cases. <i>Laboratory Medicine Online</i> , 2022, 12, 53-57.	0.2	0
3	Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study. <i>PLoS ONE</i> , 2022, 17, e0261671.	2.5	4
4	How myeloproliferative neoplasms patients' experience and expectations differ from physicians': the international MPN Landmark survey. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 444-454.	1.7	2
5	Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study. <i>Thrombosis Research</i> , 2022, 213, 114-118.	1.7	0
6	Incidence of Venous Thromboembolism: The 3 rd Korean Nationwide Study. <i>Journal of Korean Medical Science</i> , 2022, 37, e130.	2.5	7
7	Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma. <i>Annals of Hematology</i> , 2022, 101, 1217-1226.	1.8	2
8	Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura. <i>Blood Research</i> , 2022, 57, S37-S43.	1.3	2
9	Sequential eradication of <i>Helicobacter pylori</i> as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study. <i>Annals of Hematology</i> , 2022, 101, 1435-1445.	1.8	7
10	<i>Pneumocystis jirovecii</i> pneumonia in diffuse large B-cell Lymphoma treated with R-CHOP. <i>Mycoses</i> , 2021, 64, 60-65.	4.0	7
11	Clinical history of cancer-associated splanchnic vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 983-991.	3.8	12
12	Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2021, 113, 81-91.	1.6	3
13	Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962097957.	1.7	2
14	Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission?. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110011.	2.5	1
15	Updated recommendations for the treatment of venous thromboembolism. <i>Blood Research</i> , 2021, 56, 6-16.	1.3	11
16	Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. <i>Thrombosis Research</i> , 2021, 201, 63-72.	1.7	14
17	Clinical characteristics and prognostic factors of acquired haemophilia A in Korea. <i>Haemophilia</i> , 2021, 27, e609-e616.	2.1	2
18	Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2021, 100, 2567-2574.	1.8	4

#	ARTICLE	IF	CITATIONS
19	Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea. <i>Current Problems in Cancer</i> , 2021, 46, 100786.	2.0	0
20	Platelet count as an important prognostic factor for vaccine-induced immune thrombotic thrombocytopenia. <i>Blood Research</i> , 2021, 56, 129-133.	1.3	4
21	Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms. <i>Scientific Reports</i> , 2021, 11, 17819.	3.3	6
22	The 2020 revision of the guidelines for the management of myeloproliferative neoplasms. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 45-62.	1.7	13
23	Vaccine-Induced Immune Thrombotic Thrombocytopenia: First Case Report in South Korea. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
37	Drug use evaluation of opioid analgesics in pain management among patients with hematopoietic stem cell transplantation. <i>Blood Research</i> , 2020, 55, 151-158.	1.3	4
38	Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
39	Comparison of quality of life and health behaviors in survivors of acute leukemia and the general population. <i>Annals of Hematology</i> , 2019, 98, 2357-2366.	1.8	3
40	Use of Droplet Digital Polymerase Chain Reaction for Detecting Minimal Residual Disease: A Prospective Multi-Institutional Study. <i>In Vivo</i> , 2019, 33, 2273-2280.	1.3	4
41	Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy. <i>Thrombosis Research</i> , 2019, 183, 131-135.	1.7	12
42	Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy. <i>BMC Cancer</i> , 2019, 19, 358.	2.6	18
43	Prognostic Value of Platelet Count in Patients with Peripheral T Cell Lymphoma. <i>Acta Haematologica</i> , 2019, 141, 176-186.	1.4	16
44	Efficacy of parenteral glutamine supplementation in adult hematopoietic stem cell transplantation patients. <i>Blood Research</i> , 2019, 54, 23-30.	1.3	5
45	Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms. <i>Blood Advances</i> , 2019, 3, 3700-3708.	5.2	26
46	Identification of a potentially avoidable cardiopulmonary resuscitation in hematology and oncology wards. <i>BMC Palliative Care</i> , 2019, 18, 93.	1.8	3
47	Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement. <i>Cells</i> , 2019, 8, 1538.	4.1	7
48	Acute pulmonary thromboembolism caused by factor V Leiden mutation in South Korea. <i>Medicine (United States)</i> , 2019, 98, e16318.	1.0	1
49	Differential impact of anti-thymocyte globulin dosing by disease risk index in alternative donor peripheral blood stem cell transplantation in patients with acute leukemia or myelodysplastic syndrome after reduced intensity conditioning. <i>Blood Research</i> , 2019, 54, 290-295.	1.3	0
50	Incidence and predictors of venous thromboembolism in medically ill hospitalized elderly cancer patients: a prospective observational study. <i>Supportive Care in Cancer</i> , 2019, 27, 2507-2515.	2.2	8
51	Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2019, 109, 79-90.	1.6	9
52	Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. <i>Annals of Hematology</i> , 2019, 98, 151-158.	1.8	18
53	Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants. <i>Journal of Korean Medical Science</i> , 2019, 34, e52.	2.5	12
54	Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1125-1135.	1.7	11

#	ARTICLE	IF	CITATIONS
55	Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1086-1097.	3.0	59
56	The Genetic Polymorphism UGT1A4*3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18
57	Serum Free Light Chain Difference and $\hat{\Gamma}^2$ 2 Microglobulin Levels Are Risk Factors for Thromboembolic Events in Patients With AL Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 408-414.	0.4	7
58	Early Therapeutic Drug Monitoring of Posaconazole Oral Suspension in Patients With Hematologic Malignancies. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 115-119.	2.0	5
59	Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP). <i>Journal of Korean Medical Science</i> , 2018, 33, e142.	2.5	5
60	A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study. <i>PLoS ONE</i> , 2018, 13, e0205853.	2.5	10
61	BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3164.	4.1	17
62	Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study. <i>PLoS ONE</i> , 2018, 13, e0198544.	2.5	21
63	Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e176.	2.5	57
64	Incidence of venous thromboembolism in Korea from 2009 to 2013. <i>PLoS ONE</i> , 2018, 13, e0191897.	2.5	55
65	Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y. <i>Blood</i> , 2018, 132, 3876-3876.	1.4	0
66	BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors. <i>Haematologica</i> , 2017, 102, e187-e190.	3.5	13
67	Epidemiology and management of primary immune thrombocytopenia: A nationwide population-based study in Korea. <i>Thrombosis Research</i> , 2017, 155, 86-91.	1.7	46
68	Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials. <i>International Journal of Hematology</i> , 2017, 106, 229-239.	1.6	30
69	Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies. <i>Infection and Chemotherapy</i> , 2017, 49, 135.	2.3	8
70	Management of immune thrombocytopenia: Korean experts recommendation in 2017. <i>Blood Research</i> , 2017, 52, 254.	1.3	20
71	EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. <i>Oncotarget</i> , 2017, 8, 63901-63910.	1.8	30
72	Dapsone therapy for refractory immune thrombocytopenia patients: a case series. <i>Blood Research</i> , 2017, 52, 95.	1.3	12

#	ARTICLE	IF	CITATIONS
73	Pharmacological thromboprophylaxis and its impact on venous thromboembolism following total knee and hip arthroplasty in Korea: A nationwide population-based study. PLoS ONE, 2017, 12, e0178214.	2.5	28
74	Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party. Oncotarget, 2017, 8, 79414-79424.	1.8	3
75	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Oncotarget, 2017, 8, 79517-79526.	1.8	16
76	Human Herpesvirus 8â€“Unrelated Primary Effusion Lymphomaâ€“Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone. Cancer Research and Treatment, 2017, 49, 274-278.	3.0	8
77	Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. Blood Research, 2016, 51, 193.	1.3	6
78	Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea. Journal of Korean Medical Science, 2016, 31, 1579.	2.5	24
79	Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. PLoS ONE, 2016, 11, e0166245.	2.5	6
80	Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients. Journal of Clinical Laboratory Analysis, 2016, 30, 1061-1070.	2.1	0
81	Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 503-510.e3.	0.4	7
82	Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia. Annals of Hematology, 2016, 95, 1777-1786.	1.8	17
83	Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer, 2016, 19, 42-52.	5.3	230
84	Differences in characteristics between first and breakthrough neutropenic fever after chemotherapy in patients with hematologic disease. International Journal of Infectious Diseases, 2016, 44, 4-7.	3.3	12
85	Prospective Study on the Incidence of Postoperative Venous Thromboembolism in Korean Patients with Colorectal Cancer. Cancer Research and Treatment, 2016, 48, 978-989.	3.0	16
86	Epidemiology and Management of Immune Thrombocytopenia: A Nationwide Population-Based Study in Korea. Blood, 2016, 128, 4934-4934.	1.4	1
87	Analysis of Adverse Events of Dasatinib and Nilotinib in Chronic Phase Chronic Myeloid Leukemia Patients Treated Outside Clinical Trials. Blood, 2016, 128, 1902-1902.	1.4	0
88	Diagnosis of Secondary Peripheral Neurolymphomatosis: A Multi-Center Experience. Blood, 2016, 128, 4222-4222.	1.4	0
89	Prospective, Non-Randomized, Open-Label, Single-Arm, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Immunoglobulin 10% Formulation in Patients with Immune Thrombocytopenia (ITP). Blood, 2016, 128, 4938-4938.	1.4	0
90	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). Blood, 2016, 128, 4445-4445.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Quality-of-Life and Health Behaviors in Survivors of Acute Leukemia Compared with the General Population: A Population-Based Matched Case-Control Study. <i>Blood</i> , 2016, 128, 5981-5981.	1.4	0
92	Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. <i>Blood Research</i> , 2015, 50, 7.	1.3	4
93	Guidelines for the management of myeloproliferative neoplasms. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 771-788.	1.7	22
94	Impact of Intratumoral Expression Levels of Fluoropyrimidine-Metabolizing Enzymes on Treatment Outcomes of Adjuvant S-1 Therapy in Gastric Cancer. <i>PLoS ONE</i> , 2015, 10, e0120324.	2.5	7
95	Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. <i>Thrombosis Research</i> , 2015, 135, 846-851.	1.7	24
96	Five-Year Follow-up Study of Monoclonal Gammopathy of Undetermined Significance in a Korean Elderly Urban Cohort. <i>Cancer Research and Treatment</i> , 2015, 47, 215-220.	3.0	6
97	p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines. <i>Cancer Research and Treatment</i> , 2015, 47, 501-508.	3.0	29
98	Venous Thromboembolism Following L-Asparaginase Treatment in Hematologic Malignancies in Korea. <i>Blood</i> , 2015, 126, 4679-4679.	1.4	0
99	Salvage Treatment with Intracerebrospinal Fluid Thiotepa in Patients with Leptomeningeal Metastasis After Failure of Methotrexate-based Treatment. <i>Anticancer Research</i> , 2015, 35, 5631-8.	1.1	4
100	Prevention of Venous Thromboembolism, 2nd Edition: Korean Society of Thrombosis and Hemostasis Evidence-Based Clinical Practice Guidelines. <i>Journal of Korean Medical Science</i> , 2014, 29, 164.	2.5	55
101	Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism. <i>Blood Research</i> , 2014, 49, 77.	1.3	5
102	Prevalence and Risk Factors for Iron Deficiency Anemia in the Korean Population: Results of the Fifth Korea National Health and Nutrition Examination Survey. <i>Journal of Korean Medical Science</i> , 2014, 29, 224.	2.5	56
103	Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	4
104	Gastric cancer with initial bone metastasis: A distinct group of diseases with poor prognosis. <i>European Journal of Cancer</i> , 2014, 50, 2810-2821.	2.8	33
105	Factors Affecting Clinical Outcomes after CLAG/CLAG-M Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 5289-5289.	1.4	1
106	Antithrombotic Treatment and Outcomes of Splanchnic Vein Thrombosis in an International Prospective Registry: Results of 2-Year Follow-up. <i>Blood</i> , 2014, 124, 592-592.	1.4	0
107	Similar Levels of Complement Activation in Both Patients with Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome: The Report from the Korean TTP Registry. <i>Blood</i> , 2014, 124, 4195-4195.	1.4	0
108	Anemia and activities of daily living in the Korean urban elderly population: Results from the Korean Longitudinal Study on Health and Aging (KLoSHA). <i>Annals of Hematology</i> , 2013, 92, 59-65.	1.8	36

#	ARTICLE	IF	CITATIONS
109	Diagnosis and Treatment of Venous Thromboembolism in Cancer Patients. Korean Journal of Medicine, 2013, 85, 481.	0.3	1
110	Five yearsâ€™ Follow-Up Study For Frequency Of Monoclonal Gammopathy Of Undetermined Significance (MGUS) In a Korean Elderly Urban Cohort. Blood, 2013, 122, 5332-5332.	1.4	0
111	Incidence Of VTE Following Genitourinary Surgery In Korea and Evidence-Based Korean Guidelines For Preventing VTE In Patients Undergoing Genitourinary Surgery. Blood, 2013, 122, 1138-1138.	1.4	0
112	Targeting the protein kinases for anti-cancer therapy. The Korean Journal of Hematology, 2012, 47, 157.	0.7	1
113	Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. Blood, 2012, 120, 499-499.	1.4	3
114	Prevalence and Risk Factors of Iron Deficiency Anemia in Korea: The Fifth Korean Health and Nutrition Examination Survey (KNHANES V-1). Blood, 2012, 120, 5170-5170.	1.4	0
115	Head-to-Head Comparison of 5-Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndrome.. Blood, 2012, 120, 2843-2843.	1.4	23
116	Five-Years' Follow-up Study for Frequency of Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Korean Elderly Urban Cohort. Blood, 2012, 120, 5007-5007.	1.4	0
117	Diagnostic and therapeutic guideline for myeloproliferative neoplasm. Journal of the Korean Medical Association, 2011, 54, 112.	0.3	5
118	Different characteristics and prognostic impact of deep-vein thrombosis / pulmonary embolism and intraabdominal venous thrombosis in colorectal cancer patients. Thrombosis and Haemostasis, 2011, 106, 1084-1094..	3.4	33
119	Prevalence of monoclonal gammopathy of undetermined significance in an elderly urban Korean population. American Journal of Hematology, 2011, 86, 752-755.	4.1	17
120	Coinfection of hepatitis A virus genotype IA and IIIA complicated with autoimmune hemolytic anemia, prolonged cholestasis, and false-positive immunoglobulin M anti-hepatitis E virus: a case report. The Korean Journal of Hepatology, 2011, 17, 323.	1.5	8
121	A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma. Korean Journal of Internal Medicine, 2011, 26, 403.	1.7	2
122	Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine. Annals of Hematology, 2010, 89, 15-23.	1.8	10
123	Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Annals of Hematology, 2010, 89, 201-206.	1.8	30
124	Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma. Nuclear Medicine and Molecular Imaging, 2010, 44, 39-44.	1.0	13
125	Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia. Cancer Genetics and Cytogenetics, 2010, 197, 117-121.	1.0	13
126	Korean Guidelines for the Prevention of Venous Thromboembolism. Journal of Korean Medical Science, 2010, 25, 1553.	2.5	26

#	ARTICLE	IF	CITATIONS
127	Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry. <i>Acta Haematologica</i> , 2009, 122, 200-210.	1.4	28
128	Metabolic Syndrome Is Associated With Venous Thromboembolism in the Korean Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 311-315.	2.4	54
129	Extramedullary peritoneal hematopoiesis combined with tuberculosis in a patient with primary myelofibrosis. <i>Medical Oncology</i> , 2009, 26, 238-241.	2.5	6
130	Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype. <i>International Journal of Hematology</i> , 2009, 90, 1-5.	1.6	25
131	Immunoglobulin D Multiple Myeloma: Clinical Presentation, Response to Therapy and Prognostic Factors in 75 Patients; An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. <i>Blood</i> , 2009, 114, 1792-1792.	1.4	1
132	The Prognostic Impact of Fluorescent-in Situ Hybridization (FISH) and Conventional Karyotyping in Korean Multiple Myeloma Patients: A Retrospective Multicenter Study.. <i>Blood</i> , 2009, 114, 4902-4902.	1.4	1
133	Cost Analysis of Iron-Related Complications in a Single Institute. <i>Korean Journal of Internal Medicine</i> , 2009, 24, 33.	1.7	8
134	Patients with Hematologic Malignancies May Be at Higher Risk of Hepatitis B Reactivation in Spite of Lamivudine Prophylaxis.. <i>Blood</i> , 2009, 114, 1389-1389.	1.4	0
135	Incidence and Biologic Features of 5q Deletion and 5q- Syndrome in Myelodysplastic Syndrome in Korea; According to Reclassification of Myelodysplastic Syndrome by WHO 2008.. <i>Blood</i> , 2009, 114, 2778-2778.	1.4	0
136	Improved Survival of Patients with Multiple Myeloma and the Impact of Transplantation and Novel Agents: An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. <i>Blood</i> , 2009, 114, 4881-4881.	1.4	0
137	Clinical Efficacy and Tolerability of Granulocyte Transfusions for the Treatment of Febrile Neutropenia in the Patients with Hematologic Malignancies.. <i>Blood</i> , 2009, 114, 3146-3146.	1.4	0
138	Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation. <i>Thrombosis and Haemostasis</i> , 2009, 101, 547-51.	3.4	4
139	Correlation of quality of life with tumor response in patients receiving palliative chemotherapy for advanced gastrointestinal tumors. <i>Medical Oncology</i> , 2008, 25, 81-87.	2.5	7
140	Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma. <i>Medical Oncology</i> , 2008, 25, 447-450.	2.5	7
141	Venous thromboembolism in patients with pancreatic adenocarcinoma: Lower incidence in Asian ethnicity. <i>Thrombosis Research</i> , 2008, 122, 485-490.	1.7	52
142	Low Frequency and Variability of FLT3 Mutations in Korean Patients with Acute Myeloid Leukemia. <i>Journal of Korean Medical Science</i> , 2008, 23, 833.	2.5	15
143	Primary Mediastinal Synovial Sarcoma. <i>Journal of Lung Cancer</i> , 2008, 7, 29.	0.2	2
144	Low Incidence of Thromboembolism in Asian Multiple Myeloma Patients Treated with Thalidomide: Do We Really Need Prophylaxis for Thromboembolism in Asian Population?. <i>Blood</i> , 2008, 112, 5146-5146.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Changes of Platelet and Endothelial Microparticles in Patients with Venous Thromboembolism. <i>Blood</i> , 2008, 112, 3829-3829.	1.4	0
146	Donor Lymphocyte Infusions for Patients with Relapsed Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: a 10-year Experience of Seoul National University Hospital. <i>The Korean Journal of Hematology</i> , 2007, 42, 233.	0.7	0
147	Hereditary Hemolytic Anemia in Korea: a Retrospective Study from 1997 to 2006. <i>The Korean Journal of Hematology</i> , 2007, 42, 197.	0.7	15
148	Prognostic Significance of ABCB1 (MDR1) Gene Polymorphisms in De Novo Acute Myeloid Leukemia with t(8;21) or inv(16).. <i>Blood</i> , 2007, 110, 4271-4271.	1.4	1
149	Prognostic Significance of FLT3/ITD Mutation in AML1/ETO-Associated Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 3493-3493.	1.4	1
150	The Equal Activity of Azacytidine in 4 Risk Groups of IPSS in MDS.. <i>Blood</i> , 2007, 110, 4615-4615.	1.4	0
151	Epidemiological Change of Multiple Myeloma in Korea. <i>The Korean Journal of Hematology</i> , 2006, 41, 225.	0.7	11
152	A Multicenter Retrospective Analysis of Adverse Events in Korean Patients Using Bortezomib for Multiple Myeloma. <i>International Journal of Hematology</i> , 2006, 83, 309-313.	1.6	32
153	Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma. <i>Cancer Genetics and Cytogenetics</i> , 2006, 168, 124-132.	1.0	28
154	CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation. <i>Leukemia and Lymphoma</i> , 2006, 47, 1253-1259.	1.3	18
155	Diagnostic Usefulness of the Janus Kinase 2 Mutation in non-BCR/ABL Myeloproliferative Disorders. <i>Korean Journal of Internal Medicine</i> , 2006, 21, 219.	1.7	4
156	Diagnostic Usefulness of JAK2 Mutation in Manitest or Latent Polycythemia Vera and Secondary Polycythemia.. <i>Blood</i> , 2006, 108, 4901-4901.	1.4	0
157	Pharmacokinetics and Tolerability of Intravenous Busulfan in Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 5249-5249.	1.4	0
158	Evolution of FLT3 Internal Tandem Duplication at the Diagnosis, Relapse, Remission or Induction Failure during the Treatment in Acute Myeloblastic Leukemia.. <i>Blood</i> , 2006, 108, 4485-4485.	1.4	0
159	JAK2 V617F Mutation in Essential Thrombocythemia.. <i>Blood</i> , 2006, 108, 4925-4925.	1.4	0
160	A Report of AIDS-Related Lymphoma (ARL) in Korea.. <i>Blood</i> , 2006, 108, 4687-4687.	1.4	0
161	Changes in quality of life during palliative chemotherapy for solid cancer. <i>Supportive Care in Cancer</i> , 2005, 13, 515-521.	2.2	41
162	High-dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 1599-1604.	1.3	15

#	ARTICLE	IF	CITATIONS
163	Primary Gastric T-Cell Lymphoma: Clinicopathologic Features and Treatment Outcome.. Blood, 2005, 106, 3355-3355.	1.4	0
164	Nongastric Marginal Zone B-Cell Lymphoma: Analysis of 247 Cases - Clinical Presentation and Treatment Outcomes of Nongastric Marginal Zone B-Cell Lymphoma.. Blood, 2005, 106, 1491-1491.	1.4	0
165	Acute Exacerbation of Chronic Hepatitis B During Thalidomide Therapy for Multiple Myeloma: A Case Report. Korean Journal of Internal Medicine, 2004, 19, 196-198.	1.7	6
166	Clinical Features of Waldenstrom Macroglobulinemia in Korea. Korean Journal of Internal Medicine, 2004, 19, 137-140.	1.7	4
167	High Dose Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation as a First Line Treatment for Multiple Myeloma: a Korean Multicenter Study. Journal of Korean Medical Science, 2003, 18, 673.	2.5	8
168	A Multicenter, Phase III Clinical Trial of Leucogreen®(G-CSF) for Chemotherapy-Induced Neutropenia in Solid Tumors. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2003, 11, 38.	0.1	1